Oncology Clinical Trials in Dallas, TX
As of July 2026, 339 paid clinical trials are recruiting for Oncology in Dallas, Texas. Oncology trials evaluate immunotherapies, targeted therapies, antibody-drug conjugates, and combination regimens across solid tumors and blood cancers — from early-phase first-in-human studies to phase 3 registration trials. Compensation typically covers time, travel, and study visits, and many studies also include study-related medical care at no cost.
Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: .
Filter results
339 clinical trials for Oncology
·Clear filters·↓ Download CSVA Study of Disitamab Vedotin in Adults With HER2 Expressing Advanced Breast Cancer
This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.
A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)
MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy
A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
A Study of Alisertib in Patients With Extensive Stage Small Cell Lung Cancer
Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.
Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers
A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects
ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer
ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
A Trial to Evaluate the Safety and Activity of Fruquintinib in Minority Populations With Advanced, Previously Treated Colorectal Cancer
A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)
A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)
About research studies in Dallas
Dallas has approximately 1,645 recruiting research studies across a wide range of therapeutic areas. Texas hosts major cancer and cardiovascular research centers including MD Anderson Cancer Center, Baylor College of Medicine, UT Southwestern Medical Center, and the Texas Medical Center — the largest medical complex in the world.
Top Research Study Locations in Dallas
Researchers run research studies in Dallas, TX at 25 active sites. The clinics below currently host the largest number of recruiting studies — each name is followed by the conditions they focus on most.
| Site | Specializes in | Active trials |
|---|---|---|
| University of Texas Southwestern Medical Center | Heart Failure, Prostate Cancer, Advanced Breast Cancer | 203 |
| UT Southwestern Medical Center | Hypertension, Obesity, Renal Cell Carcinoma | 175 |
| UT Southwestern/Simmons Cancer Center-Dallas | Malignant Solid Neoplasm, Stage IVB Prostate Cancer AJCC v8, Acute Myeloid Leukemia | 88 |
| University of Texas Southwestern | Neuroblastoma, Cystic Fibrosis, Lymphoma, Non-Hodgkin | 63 |
| Baylor University Medical Center | Heart Failure, Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease | 49 |
| Parkland Memorial Hospital | Stage IIIB Lung Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8, Muscle Invasive Bladder Urothelial Carcinoma | 31 |
| The University of Texas Southwestern Medical Center | Anxiety, Breast Cancer, Depression Disorders | 30 |
| Mary Crowley Cancer Research | Advanced Solid Tumor, Solid Tumor, Colorectal Cancer | 29 |
| Medical City Dallas Hospital | Malignant Solid Neoplasm, Acute Myeloid Leukemia, B Acute Lymphoblastic Leukemia | 29 |
| UT Southwestern | AQP4+ NMOSD, Acute Kidney Injury, Advanced Endometrial Carcinoma | 25 |
| Baylor Scott & White Research Institute | Emphysema, Interstitial Lung Disease, Acute Respiratory Failure | 22 |
| UT Southwestern Simmons Cancer Center - RedBird | Stage IVB Prostate Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8 | 22 |
| Retina Foundation of the Southwest | Stargardt Disease, Age-Related Macular Degeneration, Amblyopia | 20 |
| VA North Texas Health Care System Dallas VA Medical Center, Dallas, TX | Cirrhosis, Acute Kidney Injury, Adult Growth Hormone Deficiency | 17 |
| GSK Investigational Site | Non-alcoholic Fatty Liver Disease, Chickenpox, HIV Infections | 16 |
| Methodist Dallas Medical Center | Achalasia, Acute Kidney Injury (AKI), BK Viremia | 16 |
| Zenos Clinical Research | Diabetic Peripheral Neuropathic Pain, Gout, Type 2 Diabetes | 16 |
| Children's Medical Center Dallas | Niemann-Pick Type C Disease, Acute Kidney Injury, Acute Kidney Injury Due to Sepsis | 15 |
| Texas Oncology | Advanced Melanoma, Advanced Non-Small-Cell Lung Cancer, Advanced/Metastatic Solid Tumors | 13 |
| Texas Oncology - DFW | Breast Cancer, Endometrial Cancer, Pancreatic Cancer | 12 |
| Clinical Trial Site | Advanced Breast Cancer, Advanced Hepatocellular Carcinoma, Breast Cancer | 10 |
| Methodist Dallas Medical Center- Clinical Research Institute | Trauma, Gastro-Intestinal Disorder, Chronic Pancreatitis | 10 |
| University of Texas Southwestern Medical Center at Dallas | Infant, Small for Gestational Age, Infant, Low Birth Weight, Infant, Newborn | 10 |
| Urology Clinics of North Texas | Non-Muscle Invasive Bladder Neoplasms, Prostate Cancer, FGFR Gene Alterations | 10 |
| Baylor Scott & White Health | Acute Myeloid Leukemia, Cancer, Distal Esophageal Spasm | 9 |
Active & Upcoming Studies in Dallas (2026)
Recruiting trials in Dallas grouped by therapeutic area, drawn from ClinicalTrials.gov. Each bucket shows the most recent example studies.
Cancer & tumors (471 active studies)
- Molecular Breast Imaging (MBI)-Guided Biopsy · Smart Breast Corp.
- Increasing CRC Screening in Community Health Centers Through Mobile Messaging Optimization · University of Colorado, Denver
Cardiovascular (130 active studies)
- Value of Potassium Magnesium Citrate in Preventing and Treating Hypertension in African Americans · Phase 2 · University of Texas Southwestern Medical Center
- Early Discharge With Subcutaneous Furosemide Versus Standard Care in Acute Heart Failure · Phase 3 · University of Texas Southwestern Medical Center
Neurology & pain (84 active studies)
- Cholinergic Enhancement of Theta · EARLY_Phase 1 · University of Texas Southwestern Medical Center
- Pediatric Epilepsy · University of Texas Southwestern Medical Center
Diabetes & metabolic (76 active studies)
- A Research Study Investigating How Well the Medicine Zenagamtide Helps People With Excess Body Weight Lose Weight Compared to Semaglutide · Phase 3 · Novo Nordisk A/S
- RAndomized EHR-based Prescribing to Improve Disease-modifying Therapies for Cardio-Kidney-Metabolic Care (RAPID-CKM) · Baylor Research Institute
Mental health & behavior (40 active studies)
- Optimizing CBSST With Executive Function Training for Schizophrenia (R33) · University of California, San Diego
- tDCS for Late-Life Depression · Andre Russowsky Brunoni
Eye & vision (33 active studies)
Pediatric (23 active studies)
- Parent-Adolescent Relationships, Emotional Regulation, and HRV in Adolescents With Depression · University of Texas Southwestern Medical Center
- Video vs. Direct Laryngoscopy for Less Invasive Surfactant Administration · University of Texas Southwestern Medical Center
HIV / STI (18 active studies)
Vaccines (9 active studies)
- A Study of mRNA-1018-H5 Pandemic Influenza Vaccine in Healthy Adults · Phase 3 · ModernaTX, Inc.
- A Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised · Phase 3 · Pfizer
Common conditions studied in Dallas
- Heart Failure (35 active studies). Heart failure trials explore SGLT-2 inhibitors, novel myosin modulators, and device-based therapies for both reduced and preserved ejection fraction.
- Breast Cancer (33 active studies). Breast cancer trials evaluate new hormone therapies, targeted drugs, and immunotherapy combinations aimed at improving survival and reducing recurrence.
- Advanced Solid Tumor (25 active studies). Recruiting Advanced Solid Tumor studies evaluate investigational treatments, diagnostics, and supportive care approaches to improve patient outcomes.
- Obesity (24 active studies). Obesity trials evaluate GLP-1 and GIP receptor agonists, novel metabolic drugs, and combined lifestyle interventions for sustainable weight loss.
- Prostate Cancer (21 active studies). Prostate cancer studies test next-generation hormone therapies, PARP inhibitors, and radioligand treatments for both localized and advanced disease.
- Endometrial Cancer (17 active studies). Recruiting Endometrial Cancer studies evaluate investigational treatments, diagnostics, and supportive care approaches to improve patient outcomes.
Leading research sponsors in Dallas
- University of Texas Southwestern Medical Center
- AstraZeneca
- Eli Lilly and Company
- Baylor Research Institute
- National Cancer Institute (NCI)
Local regulations and guidelines
Clinical trials in Texas are governed by U.S. Food and Drug Administration (FDA) regulations, Office for Human Research Protections (OHRP) standards, and federal HIPAA privacy rules. Every study is reviewed by an Institutional Review Board (IRB) to protect participant safety and ensure informed consent. Trials run in Texas must also comply with the Texas Medical Privacy Act (TMPA), which extends federal HIPAA protections to a broader range of entities handling participant data.
Compensation & what to expect
- How payment typically works
- Compensation is most often provided through reloadable electronic study cards or direct deposit, paid out per completed visit rather than as a lump sum. Amounts vary by the time required, the number of visits, and the study's complexity — overnight stays and inpatient pharmacology studies generally pay more than short outpatient surveys. The exact amount is disclosed in writing during informed consent before any visit.
- Healthy volunteers
- Healthy participants aged 18 and older can earn compensation by joining vaccine, pharmacology, and biomarker studies in Dallas. These trials check how a new drug or vaccine behaves in healthy bodies before later-phase testing. Many sites maintain a healthy-volunteer registry so you hear about new opportunities first.
- What's included beyond payment
- Most trials cover study-related medical care at no cost — physical exams, lab work, imaging, the investigational treatment itself, and follow-up visits with the research team. Insurance is not required to participate. Free check-ups and access to specialists are common reasons participants return for additional studies.
- Travel and time
- Many sponsors reimburse travel, parking, mileage, and lost wages for visit days. Long-running studies and trials that require frequent visits often raise stipends accordingly. Ask the study coordinator for the visit schedule and reimbursement policy before you commit.
- Asking about compensation
- Compensation is set per protocol and per site, so figures are not published in trial registries. The fastest way to confirm payment for a specific study is to contact the recruiting site listed on the study record. Coordinators are accustomed to this question and will quote the per-visit and total amounts up front.
How to find a clinical trial in Dallas
Hipa.ai aggregates every recruiting study in Dallas from ClinicalTrials.gov and refreshes the list daily. Use the filters above to narrow by condition, facility, age, phase, or healthy-volunteer eligibility, then click any study title to view full details — eligibility criteria, intervention, location, and sponsor contact information. To enroll, reach out to the central study contact listed on the study detail page; the research coordinator will walk you through the screening process.
Frequently asked questions
How many paid clinical trials are currently recruiting in Dallas?
There are approximately 1,645 recruiting clinical trials in Dallas, Texas listed on ClinicalTrials.gov. The number changes weekly as new studies open and others close enrollment.
Do clinical trials in Dallas pay participants?
Most recruiting trials in Dallas compensate participants for their time, travel, and study visits. Compensation varies by sponsor, study phase, and visit requirements — the exact amount is disclosed by the study team during the informed consent process.
Who can participate in a clinical trial in Dallas?
Eligibility depends on the specific study. Each trial defines its own inclusion criteria (age, diagnosis, medical history, prior treatments) and exclusion criteria. Both patients with specific conditions and healthy volunteers can qualify, depending on the study design.
What conditions are most commonly studied in Dallas?
The most common conditions under active study in Dallas include Heart Failure (35), Breast Cancer (33), Advanced Solid Tumor (25), Obesity (24), among many others. Browse the list above to explore every recruiting trial.
Are there clinical trials for healthy volunteers in Dallas?
Yes. Healthy-volunteer studies — often early-phase pharmacology or vaccine trials — recruit in Dallas on an ongoing basis. Use the "Healthy volunteers only" filter above to view trials that accept participants without the study's target condition.
How do I enroll in a clinical trial in Dallas?
Click any study title above to see the full study record, including eligibility criteria, visit schedule, and the study team's contact information. Reach out to the central contact or recruiting site directly — they will guide you through screening and informed consent.
Where can I take part in paid clinical trials in Dallas?
Recruiting research sites in Dallas include University of Texas Southwestern Medical Center, UT Southwestern Medical Center, UT Southwestern/Simmons Cancer Center-Dallas, among others. Each site lists its open studies and contact information on the study record above — call or email the site coordinator to ask about screening for a specific protocol.
What kinds of studies are recruiting in Dallas right now?
The largest active categories in Dallas are Cancer & tumors (471), Cardiovascular (130), Neurology & pain (84). Use the filters above to narrow by therapeutic area, phase, age, or healthy-volunteer eligibility.